General Information of DTT (ID: TT4TZ8J)

DTT Name Interferon-beta (IFNB1) DTT Info
Gene Name IFNB1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
3 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Interferon beta-1a DM1A6RV Multiple sclerosis 8A40 Approved [1]
PEGylated IFN beta 1-a DMRH0D5 Type-2 diabetes 5A11 Approved [2]
PLEGRIDY DMAKXW9 Multiple sclerosis 8A40 Approved [3]
------------------------------------------------------------------------------------
8 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Biferonex DM57B9J Multiple sclerosis 8A40 Phase 3 [4]
FP-1201 DM823WQ Acute lung injury NB32.3 Phase 3 [5]
NU-100 DMA16IL Multiple sclerosis 8A40 Phase 3 [6]
AZ-01, PEGylated interferon-beta DMHFUJT Multiple sclerosis 8A40 Phase 2 [6]
Interferon beta 1a DMQSA7H Discovery agent N.A. Phase 2 [7]
PF-06823859 DM8C1H4 Dermatomycosis EA60 Phase 2 [8]
ARX-424 DM4CZ2Y Multiple sclerosis 8A40 Phase 1 [6]
Gene therapy, IFN-b DMJP83V Glioblastoma multiforme 2A00.0 Phase 1 [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Clinical Trial Drug(s)
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
TV-1390 DMB7WEY Multiple sclerosis 8A40 Preclinical [10]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Maxy-10 DM31WQC Autoimmune diabetes 5A10 Terminated [11]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
5 The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
6 PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032947)
11 US patent application no. 8,669,257, Phenazine derivatives and uses thereof as potassium channel modulators.